Tandem Diabetes Care Inc. (TNDM)
| Bid | 16.12 |
| Market Cap | 1.17B |
| Revenue (ttm) | 1.06B |
| Net Income (ttm) | -96.03M |
| EPS (ttm) | -1.47 |
| PE Ratio (ttm) | -12 |
| Forward PE | -26.73 |
| Analyst | Buy |
| Ask | 17.99 |
| Volume | 1,007,464 |
| Avg. Volume (20D) | 1,653,677 |
| Open | 16.92 |
| Previous Close | 17.03 |
| Day's Range | 16.82 - 17.67 |
| 52-Week Range | 15.75 - 53.69 |
| Beta | 1.53 |
About TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technolo...
Analyst Forecast
According to 16 analyst ratings, the average rating for TNDM stock is "Buy." The 12-month stock price forecast is $49, which is an increase of 177.70% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's SkepticismTandem Diabetes Care, Inc. released its Q4 and full-year 2024 earnings after the bell yesterday, and the market has given the stock the thumbs down. Shares are down >30% in trading today, despite a be...
1 month ago · seekingalpha.com
Tandem Diabetes Care, Inc. (TNDM) Q4 2024 Earnings Call TranscriptTandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Susan Morrison - Executive Vice President & Chief Administrative Officer Jo...